Rocket Pharmaceuticals
RCKT
199 hedge funds and large institutions have $348M invested in Rocket Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 81 increasing their positions, 52 reducing their positions, and 32 closing their positions.
284% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $570K
56% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 52
50% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 32
8% more capital invested
Capital invested by funds: $323M → $348M (+$25.1M)
7% more funds holding
Funds holding: 186 → 199 (+13)
4.74% more ownership
Funds ownership: 84.33% → 89.07% (+4.7%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$12M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$11.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.1M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$9.41M |
| 5 |
Millennium Management
New York
|
+$5.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$10.5M |
| 2 |
Morgan Stanley
New York
|
-$7.64M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$5.57M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.17M |
| 5 |
Two Sigma Investments
New York
|
-$4.11M |
RCKT Hedge Fund Activity: Q1 2026 in Review
199 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2026, worth a combined $348M — up 7.8% from $323M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new RCKT positions and 32 closed out — a net gain of 16 holders — while 81 added to existing stakes and 52 trimmed.
The largest buyer was Marshall Wace, adding an estimated $12M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $10.5M sold.
- 199 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2026, up from 186 in Q4 2025.
- Funds reported $348M of Rocket Pharmaceuticals stock for Q1 2026, up 7.8% quarter-over-quarter.
- 48 funds opened new Rocket Pharmaceuticals positions in Q1 2026 and 32 closed out, a net change of +16 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2026 was Marshall Wace, an estimated $12M added.
- The largest Rocket Pharmaceuticals seller in Q1 2026 was Suvretta Capital Management, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2026.